Live Breaking News & Updates on Schering Plough Research

Stay updated with breaking news from Schering plough research. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

Mural Oncology plc spins out from Alkermes plc with $275 million in committed funding, providing a cash runway projected into 4Q 2025 Company’s lead product candidate – nemvaleukin alfa – being developed to treat a wide range of solid tumors – is currently in two potentially registrational clinical trials, both with readouts expected in 1Q 2025 Mural is also advancing engineered therapies targeting interleukin-18 and interleukin-12 with plans to nominate a development candidate for each program ....

Scott Jackson , Madam Cutler , Dave Borah , Vicki Goodman , Smithkline Beecham , Benjamin Hickey , Eli Lilly , Maiken Keson Brookes , Dsusan Altschuller , Glympse Bio , Caroline Loew , Arthur Cox , Ym Biosciences , Forum Pharmaceuticals , Jazz Pharmaceuticals , Goodwin Procter , Imclone Systems , Celator Pharmaceuticals , Exchange Commission On , Investor Relations Corporate Affairs , Schering Plough Research Institute , Mural Oncology , Nasdaq Global Market , Bristol Myers Squibb , General Counsel , Cerevel Therapeutics ,